Blue Jet Healthcare Limited has informed the Exchange about Investor Presentation
BLUEJET · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Blue Jet Healthcare reported Q2 FY26 revenue of Rs 1,655 mn, EBITDA of Rs 549 mn (33.2% margin) and PAT of Rs 521 mn, with QoQ revenue declining 53% due to channel de-stocking in the Pharma Intermediates (PI) segment. For H1 FY26, revenue grew 40% YoY to Rs 5,202 mn, EBITDA rose 55% to Rs 1,759 mn (33.8% margin) and PAT increased 49% to Rs 1,433 mn, driven by strong PI segment growth. The company remains debt-free with cash and treasury investments of Rs 3,413 mn as of September 2025, up from Rs 2,848 mn in March 2025. Key business updates include a new iodinated contrast media intermediate launched in July 2025, strong order book visibility for MRI contrast media, and 102 acres of land acquired near Vizag for Rs 42 crores with Rs 82 crores of additional capex deployed in H1 FY26.
Mixed near-term picture: Q2 dip from de-stocking may cause short-term stock pressure, but strong H1 growth, robust order pipeline, debt-free balance sheet with rising cash, and meaningful capacity expansion suggest long-term growth visibility remains intact for shareholders.